ArticleCancers2023
The Prognostic Value of the Novel Global Immune-Nutrition-Inflammation Index (GINI) in Stage IIIC Non-Small Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy.
Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 15 citations in OpenAlex.
- The Global Immune-Nutrition-Inflammation Index (GINI) in Acute Pancreatitis Severity Assessment: A Comparative Study.Digestive diseases and sciences · 2026Article
- Article
- Article
- The Global Immune-Nutrition-Inflammation Index Is Associated with Survival Outcomes and Enhances Prognostic Discrimination in Metastatic Pancreatic Cancer.Medicina (Kaunas, Lithuania) · 2026Article
- Association of the global inflammatory-nutritional index (GINI) with time to next treatment and overall survival in patients with metastatic colorectal cancer receiving third-line therapy: a real-world retrospective study.Journal of gastrointestinal oncology · 2026Article
- Uric Acid-Driven Biomarkers and Clinical Outcomes in Metastatic Pancreatic Cancer: A Multicenter Real-World Cohort Study.Diagnostics (Basel, Switzerland) · 2026Article
- The effect of immunonutritional support in patients undergoing surgery and adjuvant chemotherapy for lung cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Multimodal intervention for sarcopenia in nasopharyngeal carcinoma patients undergoing definitive treatment: a pilot randomized controlled trial protocol.Nutrition journal · 2026Article
- A composite immune-nutritional and tumor marker score predicts outcomes in LA-ESCC treated with neoadjuvant chemoimmunotherapy and surgery.Discover oncology · 2026Article
- The role of prognostic scoring systems in determining mortality and morbidity in patients with Fournier's gangrene.BMC surgery · 2026Article
- The prognostic importance of the global immune-nutrition-information index (GINI) in patients with Ras wild type metastatic colorectal cancer.Scientific reports · 2025Article
- Article
- Nutritional status of patients with driver gene mutation-negative non-small cell lung cancer after postoperative adjuvant chemotherapy.Journal of thoracic disease · 2025Article
- The Global Immune-Nutrition Inflammation Index for Predicting Coronary Slow Flow Phenomenon in Patients with Angina and No Obstructive Coronary Arteries.International journal of general medicine · 2025Article
- The global immune-nutrition-inflammation index predicts pathological response and survival in esophageal squamous cell carcinoma treated with neoadjuvant immunochemotherapy.Frontiers in nutrition · 2025Article
- Predictive Value of GINI and ALBI Grades in Esophageal Cancer Receiving Chemoradiotherapy.Current oncology (Toronto, Ont.) · 2024Article
- Global Immune-Nutrition-Inflammation Index as a novel comprehensive biomarker in predicting the radiation-induced trismus rates in locally advanced nasopharyngeal carcinoma patients.Biomolecules & biomedicine · 2024Review
- Unraveling the Predictive Value of the Novel Global Immune-Nutrition-Inflammation Index (GINI) on Survival Outcomes in Patients with Grade 4 Adult-Type Diffuse Gliomas.Current oncology (Toronto, Ont.) · 2024Article
- The Gustave Roussy Immune score (GRIm score) as a novel prognostic score for early breast cancer patients: A real-world retrospective study.International journal of medical sciences · 2024Article
- Global Immune-Nutrition-Information Index Is Independent Prognostic Factor for Gastric Cancer Patients Who Received Curative Treatment.Cancer diagnosis & prognosisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe sought to determine the prognostic value of the newly developed Global Immune-Nutrition-Inflammation Index (GINI) in patients with stage IIIC non-small cell lung cancer (NSCLC) who underwent definitive concurrent chemoradiotherapy (CCRT).
methodsThis study was conducted on a cohort of 802 newly diagnosed stage IIIC NSCLC patients who underwent CCRT. The novel GINI created first here was defined as follows: GINI = [C-reactive protein × Platelets × Monocytes × Neutrophils] ÷ [Albumin × Lymphocytes]. The receiver operating characteristic (ROC) curve analysis was used to determine the optimal pre-CCRT GINI cut-off value that substantially interacts with the locoregional progression-free (LRPFS), progression-free (PFS), and overall survival (OS).
resultsThe optimal pre-CCRT GINI cutoff was 1562 (AUC: 76.1%; sensitivity: 72.4%; specificity: 68.2%; Youden index: 0.406). Patients presenting with a GINI ≥ 1562 had substantially shorter median LRPFS (13.3 vs. 18.4 months;
conclusionThe newly developed GINI index efficiently divided the stage IIIC NSCLSC patients into two subgroups with substantially different median and long-term survival outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.